in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497-500.
21. Massarelli E, Varella-García M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. 2007; 13: 2890-6.
22. Slevos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in Adenocarcinoma of the lung. N Engl J Med. 1990; 323: 561-5.
23. Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance of p53 and KRAS for adjuvant chemotherapy in non-small cell lung cancer. J Clin Oncol. 2007; 25: 5240-7.
24. Soda M, CHoi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. Nature. 2007; 448 (7153): 561-6.
25. Shaw AT, Yeap BY, Solomon BJ, et al. Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls (abstract). J Clin Oncol. 2011; 29 (Suppl 15): Abstract 7507.
26. Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest. 2005;127: 978-83.
27. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007; 356: 800-8.
28. Vesselle H, Freeman JD, Wiens L, et al. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role. Clin Cancer Res. 2007; 13 (11): 3255-63.
29. Grupo Cooperativo Médico Quirúrgico de Carcinoma Broncogénico del Hospital Universitario 12 de Octubre. Pauta de Carcinoma Broncogénico. [acceso 3 de julio de 2015]; Disponible en: http://www.mbeneumologia.org/pautaCB/
30. Charlson M, Pompei P, Ales K, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-83.
31. Braun DP, Gupta D, Staren ED. Quality of life assesment as a predictor of survival in nonsmall cell lung cancer. BMC Cancer. 2011; 11: 353.
32. López-Encuentra A. Bronchogenic Carcinoma Co-operative Group. Comorbidity in operable lung cancer. A multicenter descriptive study on 2992 patients. Lung Cancer. 2002; 35: 263-9.
33. Tammemagi CM, Neslund-Dudas C, Simoff M, el al. Impact of comorbidity on lung cancer survival. Int J Cancer. 2003; 103 (6): 792-802.
34. Myrdal G, Lambe M, Hillerdal G, et al. Effect of delays on prognosis in patients with nonsmall cell lung cancer. Thorax. 2004; 59 (1): 45-9.
35. Annakkaya AN, Arbak D, Balbay O, et al. Effect of symptom-to-treatment interval on prognosis in lung cancer. Tumori. 2007; 93 (1): 61-7.
36. Diaconescu R, Lafond C, Whittom R. Treatment delays in non-small cell lung cancer and their prognostic implications. J Thorac Oncol. 2011; 6 (7): 1254-9.